Clinical Trial Update: Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-01-31